Onward Medical N.V. (ONWD.BR)
EUR 4.78
(-1.65%)
EUR 4.78
(-1.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -14.81 Million EUR | -18.18% |
| 2022 | -12.53 Million EUR | -373.53% |
| 2021 | -2.64 Million EUR | -75.48% |
| 2020 | -1.5 Million EUR | -431.34% |
| 2019 | -284 Thousand EUR | 49.91% |
| 2018 | -567 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -3.23 Million EUR | 9.57% |
| 2024 Q2 | -3.23 Million EUR | 0.0% |
| 2023 Q1 | -3.83 Million EUR | -2010.22% |
| 2023 FY | -194 Thousand EUR | 98.45% |
| 2023 Q4 | -3.57 Million EUR | 74.29% |
| 2023 Q3 | -13.92 Million EUR | -10411.11% |
| 2023 Q2 | 135 Thousand EUR | 103.52% |
| 2022 Q1 | -2.97 Million EUR | 9.03% |
| 2022 Q3 | -3.29 Million EUR | -2481.95% |
| 2022 Q4 | 200.5 Thousand EUR | 106.08% |
| 2022 Q2 | 138.5 Thousand EUR | 104.66% |
| 2022 FY | -12.53 Million EUR | -373.53% |
| 2021 Q1 | -2.02 Million EUR | -8.2% |
| 2021 FY | -2.64 Million EUR | -75.48% |
| 2021 Q4 | -3.26 Million EUR | 0.0% |
| 2021 Q3 | -3.26 Million EUR | -61.3% |
| 2021 Q2 | -2.02 Million EUR | 0.0% |
| 2020 Q2 | -1.79 Million EUR | 0.0% |
| 2020 Q3 | -1.87 Million EUR | -4.23% |
| 2020 Q1 | -1.79 Million EUR | 0.0% |
| 2020 FY | -1.5 Million EUR | -431.34% |
| 2020 Q4 | -1.87 Million EUR | 0.0% |
| 2019 FY | -284 Thousand EUR | 49.91% |
| 2018 FY | -567 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 2497.735% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 478.59% |
| Adocia SA | 1.38 Million EUR | 1169.892% |
| Aelis Farma SA | 12.35 Million EUR | 219.906% |
| Biophytis S.A. | -803 Thousand EUR | -1745.33% |
| Advicenne S.A. | 1.42 Million EUR | 1139.13% |
| genOway Société anonyme | 20.1 Million EUR | 173.72% |
| IntegraGen SA | 5.01 Million EUR | 395.28% |
| Medesis Pharma S.A. | -2.66 Million EUR | -456.071% |
| Neovacs S.A. | 29.31 Thousand EUR | 50649.226% |
| NFL Biosciences SA | -56.06 Thousand EUR | -26330.508% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 788.275% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | -944.044% |
| Sensorion SA | 3.78 Million EUR | 491.197% |
| Theranexus Société Anonyme | -4.63 Million EUR | -219.444% |
| TME Pharma N.V. | -127 Thousand EUR | -11567.717% |
| Valbiotis SA | 2.66 Million EUR | 655.397% |
| TheraVet SA | -530.79 Thousand EUR | -2691.656% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 1269.534% |
| argenx SE | 925.49 Million EUR | 101.601% |
| BioSenic S.A. | 543 Thousand EUR | 2828.913% |
| Celyad Oncology SA | 33 Thousand EUR | 45003.03% |
| DBV Technologies S.A. | 4.15 Million EUR | 456.237% |
| Galapagos NV | 203.73 Million EUR | 107.273% |
| Genfit S.A. | 28.22 Million EUR | 152.501% |
| GeNeuro SA | -293.8 Thousand EUR | -4943.567% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | 843.129% |
| Innate Pharma S.A. | -4.12 Million EUR | -259.573% |
| Inventiva S.A. | 17.5 Million EUR | 184.674% |
| MaaT Pharma SA | 1.65 Million EUR | 995.347% |
| MedinCell S.A. | 9.28 Million EUR | 259.539% |
| Nanobiotix S.A. | 36.2 Million EUR | 140.925% |
| Oryzon Genomics S.A. | 13.94 Million EUR | 206.238% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 765.379% |
| Oxurion NV | 104 Thousand EUR | 14348.077% |
| Pharming Group N.V. | 220.1 Million EUR | 106.732% |
| Poxel S.A. | 1000.00 EUR | 1481900.0% |
| GenSight Biologics S.A. | 3 Million EUR | 593.933% |
| Transgene SA | -28.4 Million EUR | 47.831% |
| Financière de Tubize SA | -2.02 Million EUR | -630.1% |
| UCB SA | 3.34 Billion EUR | 100.443% |
| Valneva SE | 52.83 Million EUR | 128.045% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | -378.772% |